Identification of Biomarkers for Obstructive Sleep Apnoea Syndrome
Untreated Obstructive Sleep Apnea Syndrome (OSAS) has long-term complications, namely metabolic imbalances (obesity, dislipidemia, type 2 diabetes mellitus). Until now, no molecular markers for this physiopathological connection have been identified.
This project aims to determine non-invasive biomarkers that may allow better comprehension of the metabolic consequences of OSAS, as well as assess the effect of Continuous positive airway pressure (CPAP) on these metabolic parameters.
This project will integrate the clinical, metabolic, genetic/proteomic and biologic systems to further explore the mechanisms behind OSAS, as well as the effect of the treatment with CPAP.
Obstructive Sleep Apnoea Syndrome
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Obstructive Sleep Apnoea and Associated Metabolic/Cardiovascular Disorders: Understanding Mechanisms Towards Early Diagnosis and Prognosis|
- Percentage of patients with clinical improvement [ Time Frame: 6 months ] [ Designated as safety issue: No ]Treatment efficacy of CPAP will be assessed at the end of treatment through a clinical observation.
- Frequency of occurence of biomarkers [ Time Frame: 6 months ] [ Designated as safety issue: No ]Using Mass Spectrometric Immunoassay, we will identify which biomarkers have a positive association with long-term treatment effect.
|Study Start Date:||October 2012|
|Study Completion Date:||December 2014|
|Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Patients with moderate/severe OSAS will be treated with CPAP
Patients with snoring will not be subject to treatment with CPAP
Please refer to this study by its ClinicalTrials.gov identifier: NCT02043483
|Centro Hospitalar Lisboa Norte|
|Principal Investigator:||Amélia Feliciano, MD||Centro Hospitalar Lisboa Norte|